Mirum CEO Peetz Sells $2.88m in Stock Post-Option Exercise
66d ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mirum-pharmaceuticalsinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Christopher Peetz, CEO of Mirum Pharmaceuticals, sold shares worth $2.88 million on June 2, 2026. The sale was executed following the exercise of stock options. This transaction represents one of the largest single disposals by a Mirum executive this year.
Insider transactions are monitored by institutional investors for signals on executive confidence. Large-scale sales by C-suite officers often prompt scrutiny of a company's near-term prospects. The transaction occurred as Mirum advances its commercial-stage liver disease portfolio.
The last significant sale by Peetz occurred on February 15, 2026, when he disposed of approximately $1.1 million in stock. The current sale's magnitude is 162% larger than the February transaction. Sales of this scale by biotech CEOs frequently precede periods of increased stock-specific volatility.
The biotech sector faces a challenging macro backdrop with the XBI Biotech ETF down 4% year-to-date. The transaction precedes Mirum's anticipated Q2 2026 earnings report in early August. Key catalysts for the company include prescription trend data for its lead drug, Livmarli.
Peetz sold 85,000 shares at an average price of $33.88 per share. The total sale value was $2,879,800. The transaction reduced his direct holdings by approximately 18%.
Mirum's stock closed the trading session at $34.02, down 1.7% on the day. The company's current market capitalization stands near $1.65 billion. The 30-day average trading volume for MIRM is approximately 450,000 shares.
| Metric | Pre-Sale Holding | Post-Sale Holding | Change |
|---|---|---|---|
| Direct Shares Held | ~472,000 | ~387,000 | -18% |
The sale price of $33.88 represents a 25% premium to the stock's 52-week low of $27.10. It is 12% below the 52-week high of $38.50 set in April 2026. Peer company Albireo Pharma has seen similar insider activity this quarter.
The sale may signal a neutral to cautious short-term outlook from management on the stock's valuation. It could introduce modest selling pressure on MIRM shares in the near term as the market absorbs the additional volume. Trading volumes in MIRM are expected to remain elevated for several sessions.
Small-cap biotech stocks like Catalyst Pharmaceuticals and Travere Therapeutics often see correlated moves on significant insider news from peers. A key counter-argument is that the sale was part of a pre-arranged 10b5-1 trading plan for tax planning, which would diminish its predictive signal. Documentation confirming the plan type was not immediately available.
Hedge funds with event-driven strategies are likely to increase their short interest in MIRM following the filing. Long-only institutional holders may tighten their stop-loss levels. Flow data indicates increased put option buying on the MIRM chain for July and August expirations.
Investors should monitor the next SEC Form 4 filing to determine if the sale was executed under a 10b5-1 plan. The absence of a plan designation would amplify the transaction's significance. The Q2 2026 earnings call, expected around August 8, will be critical for management commentary.
The $32.50 level represents a key technical support zone for MIRM, a breach of which could trigger further selling. Resistance sits firmly at the $35.00 mark, which has capped rallies twice in the past month. Prescription data for Livmarli from sources like IQVIA, due in mid-July, will provide a fundamental health check.
Phase 2 data readouts for Mirum's volixibat in primary sclerosing cholangitis are expected in Q4 2026. Any deviation from the expected timeline will significantly impact the stock. The broader XBI ETF's performance will also influence MIRM's direction independent of company-specific news.
A 10b5-1 plan allows corporate insiders to pre-arrange stock trades at a future date. This mechanism is designed to avoid allegations of insider trading by establishing the trade parameters when the insider is not in possession of material non-public information. The plan must be established during an open trading window and specifies amount, price, and date. If Peetz's sale was under such a plan, its significance as a negative signal is substantially reduced.
CEO sales in the commercial-stage biotech sector averaging between $1-5 million are common for portfolio diversification. The $2.88 million sale is within this range but sits at the higher end for Mirum's recent history. For context, the aggregate insider selling volume for Mirum over the past 12 months is approximately $15 million, making this sale represent nearly 20% of that annual total in a single transaction.
When an executive exercises non-qualified stock options, the spread between the grant price and the market price at exercise is taxed as ordinary income. The subsequent sale of the shares is a separate taxable event, where any further gain is taxed as a capital gain. A simultaneous exercise-and-sell transaction, common for cashless exercises, combines these events and is often used to cover the tax liability and transaction costs.
The sale's size warrants monitoring but requires confirmation of its pre-planned status for full context.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.